Legend Biotech Corp Adr (LEGN)

Nov 15, 2024

Legend Biotech stock hits 52-week low at $38.59 amid market shifts - Investing.com

Nov 15, 2024

Nov 14, 2024

Legend Biotech's SWOT analysis: stock shows promise amid CAR-T therapy growth - Investing.com India

Nov 14, 2024

Nov 14, 2024

Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential - Investing.com India

Nov 14, 2024

Nov 14, 2024

Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential By Investing.com - Investing.com South Africa

Nov 14, 2024

Nov 12, 2024

Earnings call: Legend Biotech sees robust growth in CARVYKTI sales - Investing.com

Nov 12, 2024

Nov 12, 2024

Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN

Nov 12, 2024

Nov 12, 2024

Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance

Nov 12, 2024

Nov 06, 2024

T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.

Nov 06, 2024

Nov 05, 2024

Legend Biotech's SWOT analysis: carvykti success drives stock outlook - Investing.com

Nov 05, 2024

Nov 04, 2024

Gilead Science to Report Q3 Earnings: What's in the Cards? - Yahoo Finance

Nov 04, 2024

Nov 04, 2024

Legend Biotech appoints new President for CARVYKTI - Investing.com

Nov 04, 2024

Oct 28, 2024

Legend Biotech Corp ADR (NASDAQ:LEGN) Stock Is up 15.91% From Its Low, This Stock Is Just Warming Up - Stocks Register

Oct 28, 2024

Oct 24, 2024

Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade - Yahoo Finance

Oct 24, 2024

Oct 17, 2024

Adma Biologics Inc (ADMA) Should Be Considered For The Next Few Weeks - Stocks Register

Oct 17, 2024

Oct 17, 2024

Legend Biotech shares hold Buy rating, $91 target despite Q3 CARVYKTI sales - Investing.com India

Oct 17, 2024

Oct 17, 2024

Legend Biotech shares hold as Barclays maintains $94 target - Investing.com India

Oct 17, 2024

Oct 16, 2024

Company’s Banking Stock: Dissecting a -18.35% Quarterly Revenue Decline Amid Growth - The InvestChronicle

Oct 16, 2024

Oct 16, 2024

Redburn Atlantic initates Legend Biotech Corp ADR (LEGN) rating to a Buy - Knox Daily

Oct 16, 2024

Oct 16, 2024

Li Auto Inc ADR (LI) rating downgrades by Macquarie - Knox Daily

Oct 16, 2024

Oct 16, 2024

Recent Insider Activity Suggests Potential Gains for Enovix Corporation (ENVX) - Knox Daily

Oct 16, 2024

Oct 16, 2024

BMO maintains steady target on Legend Biotech on strong sales - Investing.com

Oct 16, 2024

Oct 16, 2024

BMO maintains steady target on Legend Biotech on strong sales By Investing.com - Investing.com South Africa

Oct 16, 2024

Oct 15, 2024

Stock Performance Spotlight: Legend Biotech Corp ADR (LEGN) Ends the Day at 49.68, Down by -0.64 - The Dwinnex

Oct 15, 2024

Oct 15, 2024

Legend Biotech Corp ADR’s results are impressive - US Post News

Oct 15, 2024

Oct 15, 2024

UnitedHealth, NVIDIA lead Tuesday's afternoon market cap stock movers By Investing.com - Investing.com UK

Oct 15, 2024

Oct 11, 2024

Legend Biotech maintains shares price target on steady Q3 growth - Investing.com

Oct 11, 2024

Oct 11, 2024

Legend Biotech Corp ADR’s Mixed Bag: Down -8.63% in 6 Months, Down 1.03% in 30 Days - The InvestChronicle

Oct 11, 2024

Oct 10, 2024

Market Insights: Legend Biotech Corp ADR (LEGN)’s Notable Gain of 1.62, Closing at 48.84 - The Dwinnex

Oct 10, 2024

Oct 09, 2024

Legend Biotech shares hold strong with positive outlook on robust Carvykti sales - Investing.com

Oct 09, 2024

Oct 08, 2024

Legend Biotech Corp ADR (LEGN) is a good investment, but the stock may be overvalued - US Post News

Oct 08, 2024

Oct 08, 2024

Redburn sees growth potential for Legend Biotech stock on Carvykti demand - Investing.com

Oct 08, 2024

Oct 07, 2024

Does Legend Biotech Corp ADR (LEGN) offer a good opportunity for investors? - SETE News

Oct 07, 2024

Oct 04, 2024

Legend Biotech stock maintains positive outlook with new Philadelphia R&D facility - Investing.com

Oct 04, 2024

Oct 03, 2024

Upward Trajectory: Legend Biotech Corp ADR (LEGN) Posts a Gaine, Closing at 48.68 - The Dwinnex

Oct 03, 2024

Oct 02, 2024

Legend Biotech Corp ADR (LEGN) stock analysis: A simple moving average approach - US Post News

Oct 02, 2024

Oct 01, 2024

You might want to take a look at Legend Biotech Corp ADR (LEGN) now - SETE News

Oct 01, 2024

Sep 30, 2024

Legend Biotech shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com South Africa

Sep 30, 2024

Sep 30, 2024

BMO maintains Outperform rating on Legend Biotech shares on Carvykti data - Investing.com India

Sep 30, 2024

Sep 30, 2024

Legend Biotech shares maintain Buy rating from H.C. Wainwright - Investing.com India

Sep 30, 2024

Sep 30, 2024

Legend Biotech's SWOT analysis: carvykti success drives stock potential - Investing.com

Sep 30, 2024

Sep 30, 2024

Legend Biotech reiterates stock target, overweight on Phase III data - Investing.com

Sep 30, 2024

Sep 30, 2024

Legend Biotech stock poised for growth with compelling data on Carvykti - Investing.com

Sep 30, 2024

Sep 26, 2024

Legend Biotech Corp ADR (LEGN) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

Sep 26, 2024

Sep 25, 2024

Can you now get a good deal on Legend Biotech Corp ADR’s shares? - US Post News

Sep 25, 2024

Sep 24, 2024

There is no doubt that Legend Biotech Corp ADR (LEGN) ticks all the boxes. - SETE News

Sep 24, 2024

Sep 24, 2024

Closing Bell Recap: Legend Biotech Corp ADR (LEGN) Ends at 45.92, Reflecting a -5.38 Downturn - The Dwinnex

Sep 24, 2024

Sep 20, 2024

Analytical Lens: Exploring Legend Biotech Corp ADR (LEGN)’s Financial Story Through Ratios - The Dwinnex

Sep 20, 2024

Sep 19, 2024

What was Legend Biotech Corp ADR (LEGN)’s performance in the last session? - US Post News

Sep 19, 2024

Sep 18, 2024

European Investors Can Invest in the Future of U.S. Healthcare With This ETF - Trackinsight

Sep 18, 2024